It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.

 

Evotec and GARDP announce new partnership to discover novel antibiotics

Evotec and Galapagos enter into collaboration in the field of Fibrosis

Evotec receives milestone payment for start of Phase II clinical trial

Evotec and LEO Pharma form drug discovery alliance targeting dermatological conditions

Evotec and Immuneering to collaborate on Artificial Intelligence (“AI”) driven ligand identification for rare hereditary metabolic diseases

Ferring and Evotec form strategic research alliance in reproductive medicine and women’s health

Evotec and Celgene expand IPSC collaboration to include additional cell lines

Evotec signs agreement with Sanofi to advance early stage academic research into novel therapeutic candidates

Evotec publishes DDup 7 – Kidney diseases 2.0

Evotec and Almirall enter into research collaboration in the field of dermatological diseases

Evotec AG listed in MDAX

Evotec and Celgene enter partnership in the field of targeted protein degradation

Yumanity Therapeutics announces first clinical candidate for the potential treatment of Parkinson’s disease

Evotec and CHDI Foundation extend ongoing collaboration to fight Huntington's disease

Evotec and CENTOGENE sign global strategic partnership on drug discovery projects in rare genetic diseases

Evotec and Novo Nordisk form strategic research alliance in diabetes and obesity

Evotec partner Haplogen enters into collaboration with Bayer

Evotec repays 50% of € 140 m acquisition loan

Evotec receives milestone payment for start of Phase II trial in its multi-target alliance with Bayer

Evotec confirm closing of transaction with Sanofi to accelerate infectious disease research and development

Evotec achieves second milestone in diabetes alliance with Sanofi

Evotec and Sanofi sign definitive agreement to combat infectious diseases

Evotec forms academic BRIDGE 'LAB591’ with Arix Bioscience and Fred Hutchinson Cancer Research Center

Evotec and Celgene expand IPSC collaboration to include additional cell lines

Evotec and Celgene enter into strategic oncology partnership

Evotec reports First Quarter 2018 results and provides Corporate update

Evotec and Carna Biosciences collaborate on INDiGO platform

Evotec expands CRISPR-based technology offering with licence from ERS genomics

Evotec and Bayer Advance Third Endometriosis Programme into Phase I Clinical Development

Evotec forms collaboration with Petra Pharma on INDiGO platform

Evotec launches INDiGO®, a unique integrated drug development solution for accelerating early drug candidates into the clinic

Evotec and Apeiron Achieve First Milestone in Immuno-Oncology Alliance with Sanofi

Evotec Enters into Research Collaboration with CRTD to Discover Novel Therapies for Retinal Diseases

Evotec’s Academic Bridge LAB282 with Oxford University Celebrating One Year of Impact

Evotec Receives Clinical Milestone as Part of its Discovery Alliance with Boehringer Ingelheim

Evotec AG announces first nine-month 2017 results and corporate update

Evotec joins forces with Academic Leaders to accelerate Drug Discovery in kidney diseases and build “Neplex”

Evotec AG to report first nine-month 2017 results on 08 November 2017

New Research by Cyprotex on Transporter DDI Published in Pharmacology Research & Perspectives

Evotec and Tesaro Enter Strategic Partnership To Discover Novel Immuno-Oncology Agents

Evotec Achieves First Milestone In Neurodegeneration Alliance With Celgene

Evotec and MaRS Innovation Establish Academic Bridge “LAB150” in Toronto

Evotec to Acquire Aptuit, Expanding Leadership in External Innovation

Read our article on Form Selection Problems in the Pharmaceutical Field

Aptuit Announces Strategic Provider Agreement with Regulus Therapeutics

Aptuit's Collaboration with MGH Covered on OneNucleus Spring 2017 Newsletter

Why We Need a Culture of International Collaboration to Fight Antibiotic Resistance

Aptuit Announces Alignment of Organizational Structure to Integrated Solution Delivery: Henning Steinhagen Appointed as President, Research and Development Operations

Pharma's Almanac on Aptuit's Collaboration with Bioversys

Aptuit Selected as a Winner of Life Science Leader Global Award for Contract Drug Manufacturer in Multiple Categories

Bioversys AG and Aptuit Announce Collaboration to Identify Novel Approaches to Treat Serious Infections from Gram-negative Pathogens

Dementia Discovery Fund Acquires Small Molecule Library and Enters Strategic Partnership with Aptuit to Kickstart Dementia Drug Discovery Programmes

SAMDI Tech, Inc. and Aptuit Announce Drug Discovery Screening Partnership

Aptuit announces drug discovery collaboration with Massachusetts General Hospital (MGH) to identify novel treatments for Gram-negative infections

Chronos Therapeutics partners with Aptuit for addictive behaviour programmes

Aptuit and Chiesi Initiate Integrated Discovery Project to Identify Novel Compounds for the Treatment of Idiopathic Pulmonary Fibrosis

Aptuit Announces Expansion of Compound Library

Aptuit names Peter Gray as the new Chairman of Aptuit Holdings, LLC

Aptuit announces enhancement of integrated IND enabling services

Tim Tyson to leave as Chairman of Aptuit

Aptuit LLC and Dimension Therapeutics enter strategic partnership to advance select Dimension programs toward IND filing

Henning Steinhagen appointed as Executive Vice President Drug Discovery and Development and Site-Head Verona

Aptuit obtains renewal of French CIR tax accreditation

Aptuit announces acquisition of Kuecept Ltd

Iain Rusling, Appointed VP of Quality Management and EHS

Aptuit announces acquisition of Exquiron Biotech AG

Vince Russell, Appointed Respiratory Discovery Director

Aptuit and Icagen agree to strategic alliance

Mario Maio, Appointed Global Head of CMC

Appointment of Aptuit as a member of EU-NETVAL

Aptuit announces 16M$ investment in capacity and capability

Aptuit CEO, Jonathan Goldman, joins the Columbia University Healthcare Advisory Board

 

Other announcements

Merger

The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard